UA66800C2 - Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання - Google Patents

Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання

Info

Publication number
UA66800C2
UA66800C2 UA2000020750A UA00020750A UA66800C2 UA 66800 C2 UA66800 C2 UA 66800C2 UA 2000020750 A UA2000020750 A UA 2000020750A UA 00020750 A UA00020750 A UA 00020750A UA 66800 C2 UA66800 C2 UA 66800C2
Authority
UA
Ukraine
Prior art keywords
solution
nebulization
excipient
covering
production
Prior art date
Application number
UA2000020750A
Other languages
English (en)
Russian (ru)
Inventor
Дардер Карлос Пікорнелл
Original Assignee
Ліконса, Ліберасіон Контролада Де Сустансіас Актівас, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA66800(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ліконса, Ліберасіон Контролада Де Сустансіас Актівас, С.А. filed Critical Ліконса, Ліберасіон Контролада Де Сустансіас Актівас, С.А.
Publication of UA66800C2 publication Critical patent/UA66800C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Препарат містить інертне ядро; активний шар, який швидко розчиняється або розщеплюється у воді і отриманий з єдиного водного або водно-спиртового розчину-суспензії, до складу якого входять: активний інгредієнт формули І, II або III, що має противиразкову активність і, щонайменше, один інертний наповнювач; і шар гастро-резистивного зовнішнього покриття, отриманий з розчину, до складу якого входять ентеросолюбільний полімер і, щонайменше, один інертний наповнювач. Спосіб здійснюють шляхом виконання таких операцій: 1) нанесення покриття на інертні ядра шляхом розпилення єдиного водного або водно-спиртового розчину-суспензії; 2) просушення активного шару, утвореного в процесі розпилення на попередній стадії; і 3) нанесення покриття на наповнені ядра шляхом розпилення розчину, до складу якого входять ентеросолюбільний полімер і, щонайменше, один інертний наповнювач, що здійснюють для утворення шару гастро-резистивного зовнішнього покриття.
UA2000020750A 1997-07-31 1998-07-13 Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання UA66800C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
PCT/ES1998/000204 WO1999006032A2 (es) 1997-07-31 1998-07-13 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion

Publications (1)

Publication Number Publication Date
UA66800C2 true UA66800C2 (uk) 2004-06-15

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000020750A UA66800C2 (uk) 1997-07-31 1998-07-13 Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання

Country Status (33)

Country Link
US (1) US20020098242A1 (uk)
EP (1) EP1010423B1 (uk)
JP (1) JP3961217B2 (uk)
KR (1) KR100591488B1 (uk)
AR (1) AR013242A1 (uk)
AT (1) ATE317688T1 (uk)
AU (1) AU751609B2 (uk)
BG (1) BG64967B1 (uk)
CA (1) CA2307037C (uk)
CR (1) CR5826A (uk)
CZ (1) CZ298700B6 (uk)
DE (1) DE69833490T2 (uk)
DK (1) DK1010423T3 (uk)
ES (3) ES2137862B1 (uk)
GT (1) GT199800113A (uk)
HN (1) HN1998000113A (uk)
HR (1) HRP20000053B1 (uk)
HU (1) HU230635B1 (uk)
IL (1) IL134158A (uk)
MY (1) MY121353A (uk)
NO (1) NO20000435L (uk)
NZ (1) NZ502590A (uk)
PA (1) PA8456401A1 (uk)
PE (1) PE105199A1 (uk)
PL (1) PL192961B1 (uk)
PT (1) PT1010423E (uk)
RU (1) RU2207114C2 (uk)
SK (1) SK284892B6 (uk)
TR (1) TR200000264T2 (uk)
TW (1) TW533201B (uk)
UA (1) UA66800C2 (uk)
WO (1) WO1999006032A2 (uk)
ZA (1) ZA986893B (uk)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
BR0214372A (pt) * 2001-11-21 2004-10-26 Eisai Co Ltd Composição de um preparado contendo um composto ácido-instavel fisiologicamente ativo e processo para a produção da mesma
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
EP1524967B1 (en) * 2002-08-02 2008-03-12 Ratiopharm GmbH Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
AU2005227090B2 (en) 2004-03-22 2010-12-09 Abbott Laboratories Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
EP1728512A1 (en) * 2004-03-26 2006-12-06 Eisai R&D Management Co., Ltd. Controlled-leaching preparation and process for producing the same
WO2005097082A1 (en) 2004-03-31 2005-10-20 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
UA93384C2 (uk) 2005-07-29 2011-02-10 Солвей Фармасьютикалс Гмбх Спосіб одержання стерилізованого порошкоподібного панкреатину
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
WO2008102264A2 (en) 2007-02-20 2008-08-28 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
EP2061587A1 (en) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
EP2213305A4 (en) * 2007-11-27 2010-11-17 Ohara Pharmaceutical Co Ltd PROCESS FOR PRODUCING A PELLET SUBSTANCE
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
CL2011002432A1 (es) 2010-10-01 2012-04-20 Aptalis Pharma Ltd Composicion que comprende al menos una enzima digestiva y al menos un portador, en donde el portador comprende celulosa microcristalina que tiene un tamaño de particulas mayor que 100 um; una forma de dosificacion; el envase que la contiene; un proceso para preparar la composicion; y sus usos.
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
DK2714015T3 (en) * 2011-06-01 2017-06-19 Fmc Corp Fixed controlled release dosage forms
US10016370B2 (en) * 2011-07-14 2018-07-10 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
ES2734221T3 (es) 2011-08-08 2019-12-04 Allergan Pharmaceuticals Int Ltd Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP2016537387A (ja) 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
MX2016016907A (es) 2014-06-19 2018-04-26 Aptalis Pharma Ltd Metodo para eliminar contaminantes virales de extractos pancreaticos.
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
ZA986893B (en) 1999-01-27
ES2256943T4 (es) 2007-09-16
AR013242A1 (es) 2000-12-13
HUP0002524A2 (hu) 2001-08-28
BG104193A (en) 2000-09-29
NZ502590A (en) 2001-08-31
US20020098242A1 (en) 2002-07-25
SK1032000A3 (en) 2000-11-07
DE69833490T2 (de) 2006-10-19
CR5826A (es) 1998-09-28
ES2156699A1 (es) 2001-07-01
JP3961217B2 (ja) 2007-08-22
CZ2000344A3 (cs) 2000-06-14
HRP20000053B1 (en) 2003-10-31
HN1998000113A (es) 2000-01-06
IL134158A0 (en) 2001-04-30
HRP20000053A2 (en) 2000-08-31
JP2001511443A (ja) 2001-08-14
CZ298700B6 (cs) 2007-12-27
CA2307037A1 (en) 1999-02-11
EP1010423A2 (en) 2000-06-21
WO1999006032A2 (es) 1999-02-11
PE105199A1 (es) 1999-11-19
PL192961B1 (pl) 2006-12-29
ES2256943T3 (es) 2006-07-16
DK1010423T3 (da) 2006-05-22
TR200000264T2 (tr) 2000-09-21
PT1010423E (pt) 2006-06-30
NO20000435L (no) 2000-03-23
PL338613A1 (en) 2000-11-06
KR100591488B1 (ko) 2006-06-22
EP1010423B1 (en) 2006-02-15
CA2307037C (en) 2006-09-12
PA8456401A1 (es) 2000-09-29
WO1999006032A3 (es) 1999-08-12
ES2137862B1 (es) 2000-09-16
AU8217398A (en) 1999-02-22
DE69833490D1 (de) 2006-04-20
MY121353A (en) 2006-01-28
KR20010022439A (ko) 2001-03-15
ES2137862A1 (es) 1999-12-16
GT199800113A (es) 2000-01-18
RU2207114C2 (ru) 2003-06-27
TW533201B (en) 2003-05-21
ES2156699B1 (es) 2002-03-01
SK284892B6 (sk) 2006-02-02
IL134158A (en) 2004-08-31
BG64967B1 (bg) 2006-11-30
AU751609B2 (en) 2002-08-22
ATE317688T1 (de) 2006-03-15
HU230635B1 (hu) 2017-05-29
HUP0002524A3 (en) 2002-12-28
NO20000435D0 (no) 2000-01-27

Similar Documents

Publication Publication Date Title
UA66800C2 (uk) Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
DE59808642D1 (de) Pellet-formulierung zur behandlung des intestinaltraktes
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
Boldyrev et al. Natural histidine-containing dipeptide carnosine as a potent hydrophilic antioxidant with membrane stabilizing function: a biomedical aspect
NO156690C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater.
CA2192731A1 (en) Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof
FI871087A (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
NO900342D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-fenyl-5,6-dihydrobenz(c)acridin-7-carboxylsyrer og beslektede forbindelser.
IE801163L (en) Paromomycin derivatives
NO891114D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
ES2196174T3 (es) `derivados de sesquiterpeno de actividad antiviral.
NO20013601L (no) Nye morfolinobenzamidsalter
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
EP0192393A3 (en) Alkylaminofuranone derivatives
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
DE59801192D1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
WO1997022368A3 (de) Kovalente lipid-phosphonocarbonsäure-konjugate und ihre anwendung wie antivirale arzneimittel
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
GR3031908T3 (en) Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl cyclopentaneperhydrophenanthrene derivatives active on the cardiovascular system, a process for their preparation and pharmaceutical compositions containing same
WO1995006473A3 (en) Medical use of polysulfonic acid compound
IE811209L (en) Indole acetic acid derivatives
MX9703839A (es) Soluciones intravenosas de lubeluzol.
ECSP982605A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion